Document:

EXHIBIT 10.94

     NEITHER  THIS  WARRANT  NOR  THE  SECURITIES  INTO  WHICH  THIS  WARRANT IS
EXERCISABLE  HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR
THE  SECURITIES  COMMISSION  OF  ANY  STATE  IN  RELIANCE UPON AN EXEMPTION FROM
REGISTRATION  UNDER  THE  SECURITIES  ACT  OF  1933, AS AMENDED (THE "SECURITIES
ACT"),  AND,  ACCORDINGLY,  MAY  NOT  BE  OFFERED  OR SOLD EXCEPT PURSUANT TO AN
EFFECTIVE  REGISTRATION  STATEMENT  UNDER  THE  SECURITIES ACT OR PURSUANT TO AN
AVAILABLE  EXEMPTION  FROM  THE  REGISTRATION  REQUIREMENTS  THEREUNDER  AND  IN
COMPLIANCE  WITH  APPLICABLE  STATE  SECURITIES  OR  BLUE  SKY  LAWS.

                    -----------------------------------------

                                DERMISONICS, INC.

                      COMMON STOCK PURCHASE WARRANT NO. 103

                    -----------------------------------------

Dated:  February  15,  2007

     DERMISONICS,  INC.,  a corporation organized and existing under the laws of
the  State of Nevada (the "Company"), hereby certifies that, for value received,
VICTOR  FEIN  or  his registered assigns (the "Holder"), is entitled, subject to
the terms set forth below, to purchase from the Company up to a total of 500,000
shares  of Common Stock, $0.001 par value per share (the "Common Stock"), of the
Company  (each  such  share, a "Warrant Share" and all such shares, the "Warrant
Shares")  at an exercise price equal to $.10 per Warrant Share (hereinafter this
common  stock  purchase  warrant  is  referred  to  as  the  "Warrant"  or  the
"Warrants").  The  Warrants  may be exercised through and including February 14,
2010  (the  "Expiration  Date").  This  Warrant  is  subject  to  the  following
additional  terms  and  conditions:

     1.     Registration  of  Warrant;  Registration of Transfers and Exchanges.
            -------------------------------------------------------------------

          (a)     The  Company  shall  register this Warrant, upon records to be
maintained by the Company for that purpose (the "Warrant Register"), in the name
of  the  record Holder hereof from time to time.  The Company may deem and treat
the  registered  Holder  of  this  Warrant  as the absolute owner hereof for the
purpose  of  any  exercise hereof or any distribution to the Holder, and for all
other purposes, and the Company shall not be affected by notice to the contrary.

          (b)     The Company shall register the transfer of any portion of this
Warrant  in  the Warrant Register, upon surrender of this Warrant, with the Form
of  Assignment  attached hereto duly completed and signed, to the Company at its
address

                               Page 1 of Eight
<PAGE>
for  notice  specified  in  Section  10  along with an opinion of counsel to the
Holder  reasonably  acceptable  to  the  Company  that such transfer may be made
without  compliance  with  Federal  and  state  securities  laws.  Upon any such
registration  or  transfer,  a  new  warrant  to  purchase  Common  Stock,  in
substantially  the form of this Warrant (any such new warrant, a "New Warrant"),
evidencing  the  portion  of  this Warrant so transferred shall be issued to the
transferee  and  a  New Warrant evidencing the remaining portion of this Warrant
not  so  transferred,  if  any, shall be issued to the transferring Holder.  The
acceptance  of  the  New  Warrant  by the transferee thereof shall be deemed the
acceptance  of  such transferee of all of the rights and obligations of a holder
of  a  Warrant.

          (c)     This Warrant is exchangeable, upon the surrender hereof by the
Holder  to  the  office  of  the  Company at its address for notice specified in
Section  10  for one or more New Warrants, evidencing in the aggregate the right
to  purchase the number of Warrant Shares which may then be purchased hereunder.
Any  such  New  Warrant  will  be  dated  the  date  of  such  exchange.

     2.     Duration, Exercise and Redemption of Warrants.
            ---------------------------------------------

          (a)     This  Warrant shall be exercisable by the registered Holder on
any business day before 5:00 P.M., New York City time, at any time and from time
to time on or after the date hereof, in accordance with the Vesting Schedule, to
and  including  the  Expiration  Date.  At  5:00 P.M., New York City time on the
Expiration  Date,  the portion of this Warrant not exercised prior thereto shall
be  and  become  void  and of no value.  This Warrant shall be redeemable by the
Company  as  provided  in  Section  4,  below.

          (b)     Subject  to  Sections  1(c)  and  5,  upon  surrender  of this
Warrant,  with  the  Form of Election to Purchase attached hereto duly completed
and signed, to the Company at its address for notice set forth in Section 10 and
upon  payment  of  the Exercise Price multiplied by the number of Warrant Shares
that  the  Holder  intends  to purchase hereunder, in lawful money of the United
States of America, in cash or by certified or official bank check or checks, all
as  specified  by  the  Holder  in the Form of Election to Purchase, the Company
shall promptly (but in no event later than three business days after the Date of
Exercise  (as  defined  herein))  issue  or  cause  to be issued and cause to be
delivered  to  or upon the written order of the Holder and in such name or names
as  the Holder may designate, a certificate for the Warrant Shares issuable upon
such exercise.  Any person so designated by the Holder to receive Warrant Shares
shall  be  deemed to have become a holder of record of such Warrant Shares as of
the  Date  of  Exercise of this Warrant.  A "Date of Exercise" means the date on
which  the  Company shall have received (i) this Warrant (or any New Warrant, as
applicable),  with the Form of Election to Purchase attached hereto (or attached
to  such  New  Warrant)

                               Page 2 of Eight
<PAGE>
appropriately  completed and duly signed, and (ii) payment of the Exercise Price
for  the  number  of  Warrant  Shares  so  indicated  by the holder hereof to be
purchased.

          (c)     This  Warrant shall be exercisable, either in its entirety or,
from  time to time, for a portion of the number of Warrant Shares.  If less than
all  of  the  Warrant  Shares  which  may  be  purchased  under this Warrant are
exercised  at  any  time,  the Company shall issue or cause to be issued, at its
expense,  a New Warrant evidencing the right to purchase the remaining number of
Warrant  Shares  for  which  no  exercise  has  been  evidenced by this Warrant.

     3.     Redemption  of Warrant.  The Warrants may be redeemed by the Company
            ----------------------
at  any  time  on  30  day's  written  notice  to the Holder at the last address
therefor  as  it  shall appear upon the Warrant Register at a price of $0.01 per
Warrant  commencing  immediately  after  the Registration Date provided that the
average  closing  bid  price  per  share of Common Stock for the 30 trading days
ending  five  days prior to the date of the redemption notice of the Warrants is
at  least  $20.00  per  share.

     4.     Payment  of Taxes.  The Company will pay all documentary stamp taxes
            -----------------
attributable  to  the  issuance  of  Warrant  Shares  upon  the exercise of this
Warrant;  provided,  however,  that the Company shall not be required to pay any
tax which may be payable in respect of any transfer involved in the registration
of  any certificates for Warrant Shares or Warrants in a name other than that of
the Holder, and the Company shall not be required to issue or cause to be issued
or  deliver  or cause to be delivered the certificates for Warrant Shares unless
or  until  the person or persons requesting the issuance thereof shall have paid
to  the  Company  the  amount  of  such  tax  or  shall  have established to the
satisfaction  of  the  Company that such tax has been paid.  The Holder shall be
responsible for all other tax liability that may arise as a result of holding or
transferring  this  Warrant  or  receiving  Warrant Shares upon exercise hereof.

     5.     Replacement  of Warrant.  If this Warrant is mutilated, lost, stolen
            -----------------------
or  destroyed,  the  Company  shall  issue or cause to be issued in exchange and
substitution  for  and  upon cancellation hereof, or in lieu of and substitution
for  this  Warrant,  a New Warrant, but only upon receipt of evidence reasonably
satisfactory to the Company of such loss, theft or destruction and indemnity, if
reasonably  satisfactory  to  it.  Applicants  for  a  New  Warrant  under  such
circumstances  shall  also  comply  with  such  other reasonable regulations and
procedures  and  pay such other reasonable charges as the Company may prescribe.

     6.     Reservation  of  Warrant Shares.  The Company covenants that it will
            -------------------------------
at  all  times reserve and keep available out of the aggregate of its authorized
but  unissued  Common  Stock,  solely  for  the  purpose of enabling it to issue
Warrant  Shares  upon exercise of this Warrant as herein provided, the number of
Warrant  Shares  which  are

                               Page 3 of Eight
<PAGE>
then  issuable  and  deliverable  upon the exercise of this entire Warrant, free
from preemptive rights or any other actual contingent purchase rights of persons
other  than the Holders (taking into account the adjustments and restrictions of
Section  7).  The  Company  covenants  that  all Warrant Shares that shall be so
issuable  and deliverable shall, upon issuance and the payment of the applicable
Exercise  Price  in  accordance  with  the  terms  hereof,  be  duly and validly
authorized,  issued  and  fully  paid  and  nonassessable.

     7.     Certain  Adjustments.  The  Exercise  Price  and  number  of Warrant
            --------------------
Shares  issuable  upon  exercise  of this Warrant are subject to adjustment from
time  to  time as set forth in this Section 7.  Upon each such adjustment of the
Exercise  Price pursuant to this Section 7, the Holder shall thereafter prior to
the  Expiration  Date  be  entitled to purchase, at the Exercise Price resulting
from  such  adjustment, the number of Warrant Shares obtained by multiplying the
Exercise  Price  in effect immediately prior to such adjustment by the number of
Warrant  Shares issuable upon exercise of this Warrant immediately prior to such
adjustment and dividing the product thereof by the Exercise Price resulting from
such  adjustment.

          (a)     If the Company, at any time while this Warrant is outstanding,
(i) shall pay a stock dividend or otherwise make a distribution or distributions
on  shares  of  its  Common  Stock  (as  defined below) or on any other class of
capital stock (and not the Common Stock) payable in shares of Common Stock, (ii)
subdivide  outstanding shares of Common Stock into a larger number of shares, or
(iii)  combine  outstanding  shares  of  Common  Stock  into a smaller number of
shares,  the  Exercise  Price  shall  be  multiplied  by a fraction of which the
numerator  shall  be  the  number  of shares of Common Stock (excluding treasury
shares, if any) outstanding before such event and of which the denominator shall
be  the  number  of  shares  of Common Stock (excluding treasury shares, if any)
outstanding  after  such  event.  Any  adjustment  made pursuant to this Section
shall  become  effective immediately after the record date for the determination
of  stockholders  entitled  to  receive  such dividend or distribution and shall
become  effective  immediately  after  the  effective  date  in  the  case  of a
subdivision  or  combination,  and  shall  apply  to successive subdivisions and
combinations.

          (b)     In  case  of  any  reclassification  of  the Common Stock, any
consolidation  or merger of the Company with or into another person, the sale or
transfer  of  all or substantially all of the assets of the Company in which the
consideration  therefor  is  equity  or  equity  equivalent  securities  or  any
compulsory  share  exchange pursuant to which the Common Stock is converted into
other securities or property, then the Holder shall have the right thereafter to
exercise  this  Warrant  only  into the shares of stock and other securities and
property  receivable  upon  or  deemed  to  be  held  by holders of Common Stock
following  such reclassification, consolidation, merger, sale, transfer or share
exchange,  and  the  Holder  shall  be  entitled  upon  such

                               Page 4 of Eight
<PAGE>
event to receive such amount of securities or property of the Company's business
combination partner equal to the amount of Warrant Shares such Holder would have
been  entitled  to  had  such Holder exercised this Warrant immediately prior to
such  reclassification, consolidation, merger, sale, transfer or share exchange.
The  terms  of  any such consolidation, merger, sale, transfer or share exchange
shall  include  such  terms so as to continue to give to the Holder the right to
receive  the  securities  or  property  set  forth in this Section 7(b) upon any
exercise  following  any  such  reclassification,  consolidation,  merger, sale,
transfer  or  share  exchange.

          (c)     If the Company, at any time while this Warrant is outstanding,
shall  distribute  to  all  holders  of Common Stock (and not to holders of this
Warrant)  evidences  of  its  indebtedness  or  assets  or rights or warrants to
subscribe  for or purchase any security (excluding those referred to in Sections
7(a),  (b)  and  (d)),  then  in  each  such  case  the  Exercise Price shall be
determined  by multiplying the Exercise Price in effect immediately prior to the
record  date  fixed  for  determination of stockholders entitled to receive such
distribution  by a fraction of which the denominator shall be the Exercise Price
determined  as  of  the  record date mentioned above, and of which the numerator
shall be such Exercise Price on such record date less the then fair market value
at such record date of the portion of such assets or evidence of indebtedness so
distributed applicable to one outstanding share of Common Stock as determined by
a  nationally  recognized  or  major regional investment banking firm or firm of
independent  certified  public accountants of recognized standing (which, in all
events,  may be the firm that regularly examines the financial statements of the
Company)  (an  "Appraiser")  mutually selected in good faith by the holders of a
majority  in  interest  of  the  Warrants then outstanding and the Company.  Any
determination  made  by  the  Appraiser  shall  be  final.

          (d)     If, at any time while this Warrant is outstanding, the Company
shall  issue  or  cause  to be issued rights or warrants to acquire or otherwise
sell  or  distribute shares of Common Stock to all holders of Common Stock for a
consideration  per  share  less  than  the  Exercise Price then in effect, then,
forthwith  upon  such  issue or sale, the Exercise Price shall be reduced to the
price  (calculated  to  the  nearest  cent) determined by dividing (i) an amount
equal  to  the  sum  of  (A)  the  number  of shares of Common Stock outstanding
immediately  prior  to  such issue or sale multiplied by the Exercise Price, and
(B)  the  consideration, if any, received or receivable by the Company upon such
issue  or  sale  by  (ii) the total number of shares of Common Stock outstanding
immediately  after  such  issue  or  sale.

          (e)     For  the  purposes  of  this  Section 7, the following clauses
shall  also  be  applicable:

                               Page 5 of Eight
<PAGE>
               (i)  Record Date.  In case the Company shall take a record of the
                    -----------
holders  of  its Common Stock for the purpose of entitling the holders of Common
Stock (A) to receive a dividend or other distribution payable in Common Stock or
in securities convertible or exchangeable into shares of Common Stock, or (B) to
subscribe for or purchase Common Stock or securities convertible or exchangeable
into  shares  of  Common  Stock, then such record date shall be deemed to be the
date  of  the  issue  or  sale of the shares of Common Stock deemed to have been
issued or sold upon the declaration of such dividend or the making of such other
distribution  or  the  date  of  the  granting  of such right of subscription or
purchase,  as  the  case  may  be.

               (ii)  Treasury  Shares.  The  number  of  shares  of Common Stock
                     ----------------
outstanding  at  any given time shall not include shares owned or held by or for
the  account  of  the  Company,  and the disposition of any such shares shall be
considered  an  issue  or  sale  of  Common  Stock.

          (f)     All  calculations  under  this  Section 7 shall be made to the
nearest  cent  or  the  nearest  1/100th  of  a  share,  as  the  case  may  be.

          (g)     If:

               (i)  the  Company  shall  declare  a  dividend  (or  any  other
                    distribution)  on  its  Common  Stock;  or

               (ii) the  Company  shall  declare  a  special  nonrecurring  cash
                    dividend  on  or  a  redemption  of  its  Common  Stock;  or

              (iii) the  Company shall authorize the granting to all holders of
                    the  Common  Stock  rights  or  warrants to subscribe for or
                    purchase  any shares of capital stock of any class or of any
                    rights;  or

               (iv) the  approval  of  any  stockholders of the Company shall be
                    required  in  connection  with  any  reclassification of the
                    Common  Stock of the Company, any consolidation or merger to
                    which the Company is a party, any sale or transfer of all or
                    substantially  all  of  the  assets  of  the Company, or any
                    compulsory  share  exchange  whereby  the  Common  Stock  is
                    converted  into  other  securities,  cash  or  property;  or

               (v)  the  Company  shall  authorize  the  voluntary  dissolution,
                    liquidation  or  winding  up  of the affairs of the Company;

then the Company shall cause to be mailed to each Holder at their last addresses
as  they shall appear upon the Warrant Register, at least 30 calendar days prior
to  the  applicable

                               Page 6 of Eight
<PAGE>
record or effective date hereinafter specified, a notice stating (x) the date on
which  a  record  is to be taken for the purpose of such dividend, distribution,
redemption,  rights  or warrants, or if a record is not to be taken, the date as
of  which the holders of Common Stock of record to be entitled to such dividend,
distributions,  redemption,  rights  or warrants are to be determined or (y) the
date  on  which  such reclassification, consolidation, merger, sale, transfer or
share  exchange  is  expected  to  become effective or close, and the date as of
which it is expected that holders of Common Stock of record shall be entitled to
exchange  their  shares  of  Common Stock for securities, cash or other property
deliverable  upon  such reclassification, consolidation, merger, sale, transfer,
share  exchange, dissolution, liquidation or winding up; provided, however, that
                                                         --------  -------
the  failure to mail such notice or any defect therein or in the mailing thereof
shall  not  affect the validity of the corporate action required to be specified
in  such  notice.

     8.     Payment  of Exercise Price.  The Holder may exercise this Warrant by
            --------------------------
tendering  to  the Company cash or certified or official bank check or checks in
an  amount  calculated by multiplying the Exercise Price per share by the number
of  Warrant  Shares  the  Holder  desires  to  purchase.

     9.     Fractional  Shares.  The  Company  shall not be required to issue or
            ------------------
cause  to  be  issued fractional Warrant Shares on the exercise of this Warrant.
The  number  of full Warrant Shares which shall be issuable upon the exercise of
this  Warrant  shall be computed on the basis of the aggregate number of Warrant
Shares purchasable on exercise of this Warrant so presented.  If any fraction of
a  Warrant Share would, except for the provisions of this Section 9, be issuable
on  the  exercise  of this Warrant, the Company shall, at its option, (i) pay an
amount  in  cash equal to the Exercise Price multiplied by such fraction or (ii)
round  the  number  of  Warrant  Shares  issuable,  up to the next whole number.

     10.     Notices.  Any and all notices or other communications or deliveries
             -------
hereunder  shall  be  in  writing and shall be deemed given and effective on the
earliest  of  (i)  the  date of transmission, if such notice or communication is
delivered  via  facsimile  at  the  facsimile telephone number specified in this
Section,  (ii)  the  business  day  following  the  date  of mailing, if sent by
internationally  recognized  overnight  courier  service,  or  (iii) upon actual
receipt by the party to whom such notice is required to be given.  The addresses
for  such  communications  shall  be:

             If to the Company:  DERMISONICS, INC.
                                 c/o Bruce H. Haglund
                                 2 Park Plaza, Suite 450
                                 Irvine, California  92164
                                 Facsimile Number: (949) 733-1188

                               Page 7 of Eight
<PAGE>
             If to the Holder:   VICTOR  FEIN
                                 3000 Bronx Park East
                                 Bronx, New York 10467
                                 Facsimile Number: 718-652-4241

Either party may change the address and facsimile number to which notices are to
be  sent by delivering notice to the other party in accordance with this Section
10.

     11.     Warrant  Agent.
             --------------

          (a)     The  Company  shall serve as warrant agent under this Warrant.
Upon 30 days' notice to the Holder, the Company may appoint a new warrant agent.

          (b)     Any  corporation  into  which  the  Company or any new warrant
agent may be merged or any corporation resulting from any consolidation to which
the  Company  or  any  new  warrant agent shall be a party or any corporation to
which  the  Company  or any new warrant agent transfers substantially all of its
corporate  trust  or shareholders services business shall be a successor warrant
agent  under  this  Warrant without any further act.  Any such successor warrant
agent  shall  promptly  cause  notice  of  its succession as warrant agent to be
mailed (by first class mail, postage prepaid) to the Holder at the Holder's last
address  as  shown  on  the  Warrant  Register.

     12.     Miscellaneous.
             -------------

          (a)     This  Warrant  shall be binding on and inure to the benefit of
the  parties hereto and their respective successors and permitted assigns.  This
Warrant  may  be  amended  only in writing signed by the Company and the Holder.

          (b)     Subject to Section 12(a), above, nothing in this Warrant shall
be construed to give to any person or corporation other than the Company and the
Holder  any  legal  or equitable right, remedy or cause under this Warrant; this
Warrant  shall  be  for  the  sole  and exclusive benefit of the Company and the
Holder.

          (c)     This  Warrant  shall be governed by and construed and enforced
in  accordance  with  the internal laws of the State of Nevada without regard to
the  principles  of  conflicts  of  law  thereof.

          (d)     The  headings  herein  are  for  convenience  only,  do  not
constitute a part of this Warrant and shall not be deemed to limit or affect any
of  the  provisions  hereof.

                               Page 8 of Eight
<PAGE>
          (e)     In  case  any  one  or  more of the provisions of this Warrant
shall  be  invalid  or  unenforceable  in  any  respect,  the  validity  and
enforceability  of  the remaining terms and provisions of this Warrant shall not
in  any way be affected or impaired thereby and the parties will attempt in good
faith  to  agree  upon  a  valid  and  enforceable  provision  which  shall be a
commercially  reasonable  substitute  therefor,  and  upon  so  agreeing,  shall
incorporate  such  substitute  provision  in  this  Warrant.

     IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed
by  its  authorized  officer  as  of  the  date  first  indicated  above.

                                        DERMISONICS,  INC.

                                        By: /s/ Bruce H. Haglund
                                            --------------------
                                            Bruce  H.  Haglund,
                                            Chairman

                               Page 9 of Eight
<PAGE>
                          FORM OF ELECTION TO PURCHASE
         (To be executed by the Holder to exercise the right to purchase
               shares of Common Stock under the foregoing Warrant)

To:  DERMISONICS,  INC.

     In  accordance  with  the  Warrant  enclosed  with this Form of Election to
Purchase,  the  undersigned  hereby  irrevocably  elects to purchase ___________
shares  of  Common  Stock  ("Common  Stock"),  $0.001  par  value  per share, of
DERMISONICS,  INC.  and  encloses  herewith  $_________ in  cash or certified or
official bank check or checks, which sum represents the aggregate Exercise Price
(as  defined  in  the Warrant) for the number of shares of Common Stock to which
this  Form  of  Election to Purchase relates, together with any applicable taxes
payable  by  the  undersigned  pursuant  to  the  Warrant.

     The  undersigned  requests that certificates for the shares of Common Stock
issuable  upon  this  exercise  be  issued  in  the  name  of

Print  name  and  address:
                               ----------------------------------

                               ----------------------------------

                               ----------------------------------

                               ----------------------------------
Print  social  security  or
tax  identification  number:   ----------------------------------

     If  the  number of shares of Common Stock issuable upon this exercise shall
not  be  all  of the shares of Common Stock which the undersigned is entitled to
purchase  in accordance with the enclosed Warrant, the undersigned requests that
a  New  Warrant (as defined in the Warrant) evidencing the right to purchase the
shares of Common Stock not issuable pursuant to the exercise evidenced hereby be
issued  in  the  name  of  and  delivered  to:

Print  name  and  address:
                               ----------------------------------

                               ----------------------------------

                               ----------------------------------

                               ----------------------------------

                          (The signature page follows.)

<PAGE>
Dated:                    Name of Holder:
       ---------                             -----------------------------------

                          Signature:
                                             -----------------------------------

                          By (if entity):
                                             -----------------------------------

                          Name (if entity):
                                             -----------------------------------

                          Title (if entity):
                                             -----------------------------------

                          (Signature must conform in all respects to name of
                          holder as specified on the face of the Warrant)

<PAGE>
           [To be completed and signed only upon transfer of Warrant]

     FOR  VALUE  RECEIVED,  the  undersigned hereby sells, assigns and transfers
unto ___________________________________________________________________________
the  right  represented  by  the  within  Warrant  to  purchase ________________
shares  of Common Stock of DERMISONICS, INC. to which the within Warrant relates
and  appoints the Secretary of DERMISONICS, INC. attorney to transfer said right
on  the  books  of  DERMISONICS,  INC.  with  full  power of substitution in the
premises.

Dated:                    Name of Holder:
       ---------                             -----------------------------------

                          Signature:
                                             -----------------------------------

                          By (if entity):
                                             -----------------------------------

                          Name (if entity):
                                             -----------------------------------

                          Title (if entity):
                                             -----------------------------------

                          (Signature must conform in all respects to name of
                          holder as specified on the face of the Warrant)

Name  and  Address  of  Transferee:
                                        -----------------------------

                                        -----------------------------

                                        -----------------------------

In  the  presence  of:

---------------------------------------EXHIBIT 10.95

"NEITHER  THIS  PROMISSORY  NOTE  NOR  THE  SECURITIES  INTO  WHICH THIS NOTE IS
CONVERTIBLE  HAVE  BEEN  REGISTERED  UNDER  THE  U.S. SECURITIES ACT OF 1933, AS
AMENDED (THE "SECURITIES ACT") OR ANY OTHER SECURITIES LAWS AND HAVE BEEN ISSUED
IN  RELIANCE UPON THE EXEMPTION FROM SUCH REGISTRATION CONTAINED IN REGULATION S
UNDER  THE  SECURITIES  ACT.  THE SECURITIES REPRESENTED BY THIS CERTIFICATE MAY
NOT  BE  OFFERED, SOLD OR TRANSFERRED WITHIN THE UNITED STATES OR TO, OR FOR THE
ACCOUNT  OR BENEFIT OF, ANY "U.S. PERSON" (AS SUCH TERM IS DEFINED IN REGULATION
S)  EXCEPT IN ACCORDANCE WITH REGULATION S, PURSUANT TO A REGISTRATION UNDER THE
SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM REGISTRATION UNDER THE
SECURITIES  ACT."

                          CONVERTIBLE PROMISSORY NOTE

US  $25,000.00                                               February  15,  2007

     FOR  VALUE  RECEIVED,  DERMISONICS,  INC.,  a  Nevada corporation having an
office  at  2  Park  Plaza,  Suite  450,  Irvine,  California 92614, U.S.A. (the
"Company"),  hereby  promises  to  pay  to  EurXchange  Consulting Ltd. at #534,
34A-2755  Lougheed  Highway,  Port Coquitlam, B.C., V3B 5Y9, Canada, or its duly
registered  assigns  (each  a  "Holder"),  on February 14, 2008 ("Maturity"), or
earlier upon prepayment of this Note as provided herein, the principal sum of US
$25,000.00,  together with interest (computed on the basis of a 365-day year) on
the  unpaid principal balance at the rate of 10% per annum, payable on the first
anniversary  of  the  Note  and  at  Maturity.

     The  principal  amount of this Note and all accrued interest thereon may be
prepaid  by  the  Company  written notice to the Holder and without a prepayment
penalty.  Upon  any  prepayment of this Note, all accrued but unpaid interest on
the principal amount shall be paid to the Holder on the date of prepayment.  All
payments  hereunder  shall  be  applied  first  to  interest  then to principal.

     All  payments of principal and interest shall be made in lawful currency of
the  United  States  of America in immediately available funds before 11:00 a.m.
California  time  on  the  due date thereof at the coordinates for the Holder on
file  with  the  Company,  or in such other manner or at such other place as the
Holder  of  this  Note  designates  in  writing.

     Subject to and in compliance with the provisions hereof, the Holder may, on
an  event  of  default,  as  described  below, convert all or any portion of the
outstanding  principal  balance  of  this  Note as of such payment or prepayment
date,  and  all  or  any

                                        1
<PAGE>
portion  of  the  interest accrued hereon to such date, into shares ("Conversion
Shares")  of  the  common  stock,  $.001  par value, of the Company (the "Common
Stock"),  at  a  conversion  price equal to the lesser of US $0.10 or 70% of the
average  of the three lowest closing bid prices per share of Common Stock during
the 30 trading days immediately prior to any such conversion.  The Holder hereof
shall  communicate  its intention to convert all or any portion of the principal
amount  of  this  Note  and  all or any portion of interest accrued through such
conversion  date  by surrendering this Note, with the Form of Notice of Election
to  Convert  attached  hereto  duly  completed and signed, to the Company at its
address  for  notice  set  forth  elsewhere  herein.

     In  the  event  of  a conversion by the Holder of all or any portion of the
outstanding  principal  balance  of  this Note and all or any portion of accrued
interest  thereon  into  shares  of the Common Stock, the Company will issue and
deliver  to  the Holder, as soon as practical after the Company's receipt of the
Notice  of Election a certificate evidencing the shares of Common Stock issuable
upon  any  such  conversion.

     If  the  Holder  elects to convert less than the entire principal amount of
this Note and interest accrued to the date of such conversion, the Company shall
issue  or  cause to be issued and delivered to the Holder, at its expense, a new
promissory  note  evidencing  the  outstanding amount of principal due hereunder
after  giving  effect  to  the  amount  applied  to  the  conversion, which such
promissory  note  shall, except as to the principal amount thereof, be identical
to  this  Note  in  all  respects.

     The  Company covenants that it will at all times reserve and keep available
out  of  the  aggregate  of its authorized but unissued and otherwise unreserved
Common  Stock,  solely for the purpose of enabling it to issue Conversion Shares
upon conversion of this Note as herein provided, the number of Conversion Shares
which are then issuable and deliverable upon the conversion of the entire amount
due  under  this  Note,  free  from  preemptive  rights  or any other contingent
purchase rights of persons other than the Holder. The Company covenants that all
Conversion Shares so issuable and deliverable shall, upon issuance in accordance
with the terms hereof, be duly and validly authorized, issued and fully paid and
nonassessable.

     Except  as  provided  elsewhere herein, if the Company shall fail to make a
payment of principal or interest when due and such failure shall continue for 10
days  after  notice of such failure; or shall make an assignment for the benefit
of  creditors,  file  a  petition  in  bankruptcy,  be  adjudicated insolvent or
bankrupt,  suffer an order for relief under any federal bankruptcy law, petition
or  apply  to  any  tribunal for the appointment of a custodian, receiver or any
trustee for the Company or any substantial part of its assets, or shall commence
any  proceeding  under any bankruptcy, reorganization, arrangement, readjustment
of  debt,  dissolution  or  liquidation  law  or

                                        2
<PAGE>
statue  of  any  jurisdiction,  whether  now or hereafter in effect; or if there
shall  have  been filed any such petition or application, or any such proceeding
shall  have  been  commenced  against  the  Company,  which remains undismissed,
unstayed  or unbonded for a period of 30 days or more; or if the Company, by any
act  or  omission shall indicate consent to, approve or acquiescence in any such
petition,  application or proceeding or the appointment of a custodian, receiver
or  any  trustee  for  all  or any substantial part of its properties, or if the
Company shall allow such custodianship, receivership, or trusteeship to continue
undischarged,  unstayed  or  unbonded  for  a  period of 30 days or more, or the
Company violates any term or provision of this Note and same remains uncured for
a period of 30 days after notice thereof by the Holder of this Note, then and in
any such event, the outstanding principal amount of this Note, together with all
accrued  and  unpaid  interest  thereon, shall be and become immediately due and
payable.

     Anything  contained  in  this  Note to the contrary notwithstanding, in the
event  this  Note is placed in default as a result of the Company's inability to
pay the amounts due hereunder when due, the Company shall have the right to cure
such  default  during  the  30-day  period  from  its  receipt of declaration of
default.

     All  notices  and other communications provided for herein shall be sent by
registered  or certified mail, return receipt requested, or by personal delivery
or  via  a nationally recognized overnight courier to the Holder or the Company,
at  their  respective addresses as set forth herein, or to such other address as
to  which  either  party may advise the other by notice given in accordance with
this  provision.  All  such  notices  shall  be deemed given upon the earlier of
receipt  or  within  five  business  days  of  mailing  if  receipt  is refused.

     Upon  notice  to  the Company as provided for hereinabove, the Holder shall
have  the  right  to  assign  this  Note.

     Notwithstanding  any other provision of this Note, interest under this Note
shall  not  exceed  the maximum rate permitted by law; and if any amount is paid
under  this  Note as interest in excess of such maximum rate, then the amount so
paid will not constitute interest but will constitute a prepayment on account of
the  principal  amount  of  this  Note.

     All  payments  under  this  Note  shall be made without defense, set-off or
counterclaim,  free  and  clear  of  and  without deduction for any taxes of any
nature  now  or  hereafter  imposed.

     The  undersigned  agrees  to  pay  on demand all expenses of collecting and
enforcing this Note, including, without limitation, reasonable expenses and fees

                                        3
<PAGE>
of  legal  counsel,  court  costs  and  the  cost  of  appellate  proceedings.

     The  provisions  of  this Note shall in all respects be construed according
to,  and  the  rights  and  liabilities  of  the parties hereto and shall in all
respects  be  governed  by, the laws of the State of Nevada.  This Note shall be
deemed  a  contract  made  under  the  laws  of  the State of Nevada to be fully
performed  therein,  and the validity of this Note and all rights an liabilities
hereunder  shall be determined under the laws of said State without reference to
the  conflicts  of  laws  provisions  thereof.   For  purposes of any proceeding
involving  this  Note  or  any  of  the  obligations  of  the  undersigned,  the
undersigned  hereby  submits  to the non-exclusive jurisdiction of the courts of
the  State  of  Nevada  and  of  the  United States having jurisdiction in Clark
County,  State of Nevada, and agrees not to raise and waives any objection to or
defense  based  upon  the  venue  of  any  such  court  or  based upon forum non
conveniens.  The  undersigned agrees not to bring any action or other proceeding
with respect to this Note or with respect to any of its obligations in any other
court  unless  such  courts  of  the  State  of  Nevada and of the United States
determine  that  they  do  not  have  jurisdiction  in  the  matter.

     This  Note  may  be  amended  only  by a written instrument executed by the
Company  and  the  Holder.

     IN WITNESS WHEREOF, DERMISONICS, INC. has caused this Promissory Note to be
executed  in  its  corporate  name  by its President, thereunto duly authorized.

Dated:  February 15, 2007

                                        DERMISONICS,  INC.

                                        By: /s/ Bruce H. Haglund
                                            --------------------
                                            Bruce  H.  Haglund,
                                            Chairman

                                        4
<PAGE>
                      Form of Notice of Election to Convert

     The undersigned Holder hereby elects to convert $________ of the amount due
under  that  certain  promissory note made by Dermisonics, Inc. in the principal
amount  of US $25,000.00 dated February 15, 2007 (the "Note") into _____________
shares  of  Common  Stock at a conversion price of the the lesser of US $0.10 or
70%  of  the  average of the three lowest closing bid prices per share of Common
Stock  during  the  30  trading  days  immediately  prior  to  the  conversion.
Capitalized  terms  used  herein  and  not otherwise defined have the respective
meanings  set  forth  in  the  Note.

     In  connection  with  the  conversion  of  the Note, the undersigned hereby
represents,  warrants and covenants to, and agrees with, the Company as follows:

          (a)  The  undersigned understands and acknowledges that the Conversion
          Shares  have  not been and will not be registered under the Securities
          Act  and may not be offered or sold in the United States or to, or for
          the  benefit of, any "U.S. person" (as defined in Regulation S, a copy
          of  which  previously  has  been  delivered to the Holder), unless the
          Conversion  Shares  are  registered  under  the Securities Act or such
          offer  or  sale is made pursuant to an exemption from the registration
          requirements  of  the  Act.

          (b)  The  Conversion  Shares are being offered and sold by the Company
          pursuant  to the terms of the Note and Regulation S, which permits the
          transfer  of  the  Conversion  Shares  only  to  non "U.S. Persons" in
          "off-shore  transactions"  (as  defined  in  Regulation  S).

          (c)  The  Holder is not acquiring the Conversion Shares as a result of
          or  in  connection  with  any activity that would constitute "directed
          selling  efforts" (within the meaning given that term in Regulation S)
          in the United States and will not undertake any such "directed selling
          efforts"  in  connection  with  the  Conversion  Shares in the future.

          (d)  The  Holder  is  not  a  "U.S. Person," as defined in Rule 904 of
          Regulation  S.

          (e)  The  Holder was outside the United States at the time it executed
          this  Notice.

          (f) Unless registered under the Securities Act, the Holder agrees that
          any  offer,  sale or transfer of the Conversion Shares or any interest
          therein  to any non "U.S. Person" shall be made in accordance with the
          provisions  hereof, the Note and Regulation S, and that the Company is
          under  no  obligation  to

                                        5
<PAGE>
          register  or  recognize  and  may  refuse  the transfer of any of such
          securities  by  the undersigned unless said offer, sale or transfer is
          made in accordance with the provisions hereof, the Note and Regulation
          S. The following provisions, among others which now exist or which may
          hereafter be enacted, apply to any proposed offer, sale or transfer of
          the  securities  to  a  non "U.S. Person;" provided, however, that the
          Company  may  refuse to register the transfer of any Conversion Shares
          despite a sale or transfer in conformity with the provisions described
          below  and  Regulation  S, if it reasonably believes that such sale or
          transfer  is being made in bad faith not in conformity with Regulation
          S:

               (i)  The  Holder  (and any subsequent holder of any of Conversion
          Shares  which are transferred in accordance with the provisions hereof
          and  Regulation  S)  must  certify  in writing that neither record nor
          beneficial  ownership  of  any  of  such  securities,  or any interest
          therein,  as  the  case may be, has been offered or sold in the United
          States  or  to  or  for  the  account  or  benefit of any U.S. Person.

               (ii)  Any  proposed  transferee  of  Conversion  Shares  must (A)
          certify  in  writing  that  it is not a U.S. Person and that it is not
          acquiring  such securities for the account or benefit of a U.S. Person
          or  if  such  transferee  is  a  U.S.  Person  that  it  acquired such
          securities  in  a  transaction that did not require registration under
          the  Act  and that it agrees to be bound by the restrictions on resale
          of any of such securities set forth herein and Regulation S; (B) agree
          in  writing  to  resell  such  securities  only in accordance with the
          provisions  hereof,  Regulation  S, pursuant to registration under the
          Securities  Act,  or  pursuant  to  an  available  exemption  from
          registration  and  must  agree  in  writing  not  to engage in hedging
          transactions  with  regard  to  any  of  such  securities  unless  in
          compliance  with  the  Securities Act; and (C) agree in writing to the
          placement  of  a  legend  on  the  certificate(s)  representing  such
          securities substantially in the form set forth in Section 2(g), below,
          and  to  the  placement  of  a  stop  transfer  on  the  Note  and the
          Conversions  Shares  on  the stock books and records maintained by the
          Company  or  its  transfer  agent.

          (g)  Legend  on  Certificates.  The  Conversion  Share are "restricted
          securities"  as  that  term  is  defined  in  Rule  144  ("Rule  144")
          promulgated  under  the  Securities  Act  and  are  subject  to  the
          restrictions on transfer imposed therein and pursuant to Regulation S.
          The  Holder  agrees  and  acknowledges that the Conversion Shares will
          bear  a  restrictive  legend  in  substantially  the  following  form:

                                        6
<PAGE>
     "THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED
     UNDER  THE  U.S.  SECURITIES  ACT OF 1933, AS AMENDED (THE "SECURITIES
     ACT")  OR  ANY  OTHER SECURITIES LAWS AND HAVE BEEN ISSUED IN RELIANCE
     UPON  THE  EXEMPTION  FROM SUCH REGISTRATION CONTAINED IN REGULATION S
     UNDER  THE  SECURITIES  ACT.  THE  SECURITIES  REPRESENTED  BY  THIS
     CERTIFICATE  MAY NOT BE OFFERED, SOLD OR TRANSFERRED WITHIN THE UNITED
     STATES  OR TO, OR FOR THE ACCOUNT OR BENEFIT OF, ANY "U.S. PERSON" (AS
     SUCH  TERM  IS  DEFINED  IN  REGULATION  S)  EXCEPT IN ACCORDANCE WITH
     REGULATION  S,  PURSUANT TO A REGISTRATION UNDER THE SECURITIES ACT OR
     PURSUANT  TO  AN  AVAILABLE  EXEMPTION  FROM  REGISTRATION  UNDER  THE
     SECURITIES  ACT."

          (h) The Holder shall not engage in any activity for the purpose of, or
          which  may  reasonably be expected to have the effect of, conditioning
          the  market  in the United States for the Conversion Shares, or offer,
          sell or transfer the Conversion Shares, or any interest therein to, or
          for  the  account  of  benefit  of,  a  U.S.  Person.

          (i) The Holder will not, directly or indirectly, engage in any hedging
          transactions  (as  such  term  is  defined in the Securities Act) with
          respect to the Common Stock unless such transactions are in compliance
          with  the  Securities  Act.

          (xi)  If  the  Holder  publicly  re-offers  all  or  any  part  of the
          Conversion  Shares  in  the  United States, the Holder (and/or certain
          persons  who  participate  in  any such re-offer) may be deemed, under
          certain  circumstances,  to  be an "underwriter" as defined in Section
          2(11)  of  the  Act. If the Holder plans to make any such re-offer, it
          will  consult  with its counsel prior to any such re-offer in order to
          determine its liabilities and obligations hereunder, Regulation S, the
          Securities  Act  and  any  applicable  state  securities  laws.

Dated:           ,                      Name  of  Holder:
       ---------  ----

                                        (Print)
                                                ---------------------------

                                        By:
                                            -------------------------------
                                        Name:
                                              -----------------------------
                                        Title:
                                               ----------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00123-of-00352.parquet"}]]